• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Needle or Drip?-Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases.

作者信息

Outtier An, Ferrante Marc

机构信息

Department of Gastroenterology and Hepatology, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium.

Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Louvain, Belgium.

出版信息

Dig Dis Sci. 2025 Jan;70(1):17-18. doi: 10.1007/s10620-024-08772-4. Epub 2024 Dec 4.

DOI:10.1007/s10620-024-08772-4
PMID:39633231
Abstract
摘要

相似文献

1
Needle or Drip?-Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases.打针还是滴注？——英夫利昔单抗和维多珠单抗静脉注射与皮下注射治疗炎症性肠病的真实世界比较
Dig Dis Sci. 2025 Jan;70(1):17-18. doi: 10.1007/s10620-024-08772-4. Epub 2024 Dec 4.
2
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience.炎症性肠病患者对从静脉注射英夫利昔单抗或维多珠单抗转换为皮下制剂的接受度：南希的经验。
J Clin Med. 2022 Dec 8;11(24):7296. doi: 10.3390/jcm11247296.
3
Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.生物序贯治疗中皮下注射英夫利昔单抗治疗炎症性肠病的成本效果分析。
Inflamm Bowel Dis. 2023 Jun 1;29(6):898-913. doi: 10.1093/ibd/izac160.
4
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.比较皮下注射和静脉注射英夫利昔单抗与维得利珠单抗治疗 TNF 初治成人炎症性肠病患者的维持治疗效果：系统文献回顾和网络荟萃分析。
Dig Dis Sci. 2024 May;69(5):1808-1825. doi: 10.1007/s10620-023-08252-1. Epub 2024 Mar 18.
5
Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.炎症性肠病患者从静脉注射维得利珠单抗转为皮下注射维得利珠单抗维持治疗的真实体验。
Eur J Gastroenterol Hepatol. 2024 Oct 1;36(10):1193-1201. doi: 10.1097/MEG.0000000000002816. Epub 2024 Jul 8.
6
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.皮下注射英夫利昔单抗 CT-P13 和维得利珠单抗在临床实践中的应用：多利益相关方立场声明，强调需要进行上市后研究。
J Crohns Colitis. 2022 Aug 4;16(7):1059-1069. doi: 10.1093/ecco-jcc/jjac009.
7
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.静脉注射向维得利珠单抗皮下维持治疗炎症性肠病的真实世界经验。
Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 2022 Jul 23.
8
Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience.炎症性肠病患者从静脉注射维多珠单抗转换为皮下注射维多珠单抗后维多珠单抗血清浓度、疗效及安全性的真实世界研究：单中心经验
Pharmaceuticals (Basel). 2023 Feb 5;16(2):239. doi: 10.3390/ph16020239.
9
Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.炎症性肠病中维多珠单抗和英夫利昔单抗的输注给药计费
J Med Econ. 2018 Nov;21(11):1102-1109. doi: 10.1080/13696998.2018.1511568. Epub 2018 Sep 3.
10
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.重新调整英夫利昔单抗治疗方案：皮下注射英夫利昔单抗为患者提供了更便捷和更有益的治疗选择。
Clin Drug Investig. 2022 Jun;42(6):477-489. doi: 10.1007/s40261-022-01162-6. Epub 2022 Jun 3.

本文引用的文献

1
Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study.炎症性肠病患者由皮下注射英夫利昔单抗转换为维得利珠单抗：一项前瞻性多中心研究。
Dig Dis Sci. 2024 Dec;69(12):4458-4466. doi: 10.1007/s10620-024-08631-2. Epub 2024 Sep 30.
2
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.皮下注射英夫利昔单抗 CT-P13 和维得利珠单抗在临床实践中的应用：多利益相关方立场声明，强调需要进行上市后研究。
J Crohns Colitis. 2022 Aug 4;16(7):1059-1069. doi: 10.1093/ecco-jcc/jjac009.
3
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
皮下注射维得利珠单抗治疗中重度活动期克罗恩病的疗效和安全性：VISIBLE 2 随机试验结果。
J Crohns Colitis. 2022 Jan 28;16(1):27-38. doi: 10.1093/ecco-jcc/jjab133.
4
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.随机对照试验：英夫利昔单抗 CT-P13 在炎症性肠病中的皮下与静脉输注维持治疗。
Gastroenterology. 2021 Jun;160(7):2340-2353. doi: 10.1053/j.gastro.2021.02.068. Epub 2021 Mar 5.
5
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.在一项溃疡性结肠炎患者的随机试验中，维得利珠单抗皮下制剂的疗效和安全性。
Gastroenterology. 2020 Feb;158(3):562-572.e12. doi: 10.1053/j.gastro.2019.08.027. Epub 2019 Aug 28.
6
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.阿达木单抗诱导中重度活动性溃疡性结肠炎临床缓解的随机对照试验结果。
Gut. 2011 Jun;60(6):780-7. doi: 10.1136/gut.2010.221127. Epub 2011 Jan 5.
7
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.阿达木单抗用于曾接受英夫利昔单抗治疗的克罗恩病诱导治疗：一项随机试验。
Ann Intern Med. 2007 Jun 19;146(12):829-38. doi: 10.7326/0003-4819-146-12-200706190-00159. Epub 2007 Apr 30.
8
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.英夫利昔单抗维持治疗克罗恩病：ACCENT I随机试验
Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4.